,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June 30, 2021 was $62.6 billion.*",62.6,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,gild,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June 30, 2021 was $62.6 billion.",$62.6 billion,MONEY,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June 30, 2021 was $62.6 billion.","['aggregate market value', 'non affiliates of registrant', 'closing price of Common Stock', 'closing price on Nasdaq Global Select Market', 'closing price on June', 'aggregate market value', 'common equity', 'non affiliates', 'closing price', 'Common Stock', 'Nasdaq Global Select Market']","['closing price of Common Stock', 0.9584078788757324, 'what is closing price of Common Stock ?', '$62.6 billion']",closing price of Common Stock,0.9584078788757324,what is closing price of Common Stock ?,$62.6 billion,Nasdaq Global Select Market
1,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",5,"['Preferred stock, authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,gild,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",5,CARDINAL,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",[],"['shares authorized', 0.9347191452980042, 'What is 5 ?', 'shares authorized']",shares authorized,0.9347191452980042,What is 5 ?,shares authorized,shares authorized
2,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",5,"['Preferred stock, authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,gild,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",5,CARDINAL,"Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding",[],"['shares authorized', 0.9347191452980042, 'What is 5 ?', 'shares authorized']",shares authorized,0.9347191452980042,What is 5 ?,shares authorized,Preferred stock shares authorized
3,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","5,600","['Common stock, authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","5,600",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['authorized', 0.986136794090271, 'What is 5,600 ?', 'authorized']",authorized,0.986136794090271,"What is 5,600 ?",authorized,Authorized shares of common stock
4,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","5,600","['Common stock, authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","5,600",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['authorized', 0.986136794090271, 'What is 5,600 ?', 'authorized']",authorized,0.986136794090271,"What is 5,600 ?",authorized,authorized shares of common stock
5,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254","['Common stock, issued']",us-gaap_CommonStockSharesIssued,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['shares', 0.5784415602684021, 'What is 1,254 ?', 'shares']",shares,0.5784415602684021,"What is 1,254 ?",shares,Shares of common stock
6,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254","['Common stock, outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['shares', 0.5784415602684021, 'What is 1,254 ?', 'shares']",shares,0.5784415602684021,"What is 1,254 ?",shares,shares issued and outstanding
7,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254","['Common stock, outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['shares', 0.5784415602684021, 'What is 1,254 ?', 'shares']",shares,0.5784415602684021,"What is 1,254 ?",shares,Common stock shares outstanding
8,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254","['Common stock, issued']",us-gaap_CommonStockSharesIssued,sharesItemType,gild,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020","1,254",CARDINAL,"Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December 31, 2021 and 2020",[],"['shares', 0.5784415602684021, 'What is 1,254 ?', 'shares']",shares,0.5784415602684021,"What is 1,254 ?",shares,"shares outstanding as of December 31, 2021 and 2020"
9,"Gilead Sciences, Inc. (""Gilead,"" ""we,"" ""our"" or ""us"") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.",35,['Number of countries in which entity operates'],us-gaap_NumberOfCountriesInWhichEntityOperates,integerItemType,gild,"We operate in more than 35 countries worldwide, with headquarters in Foster City, California.",more than 35,CARDINAL,"We operate in more than 35 countries worldwide, with headquarters in Foster City, California.",['headquarters in Foster City'],"['', 0, '', '']",,0.0,,,countries worldwide
10,"We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision maker (""CODM""), manages and allocates resources to the operations of our company on an entity wide basis. Managing and allocating resources on an entity wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (""R&D"") projects based on unmet medical need and, as necessary, reallocate resources among our internal R&D portfolio and external opportunities to best support the long term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.",one,['Number of operating segments'],us-gaap_NumberOfOperatingSegments,integerItemType,gild,"We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need.",one,CARDINAL,"We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need.","['development of innovative medicines', 'discovery in areas', 'areas of unmet medical need', 'operating segment', 'innovative medicines', 'unmet medical need']","['operating segment', 0.9040085673332214, 'how many operating segment ?', 'one']",operating segment,0.9040085673332214,how many operating segment ?,one,operating segment
11,"We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",735,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,gild,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$735 million,MONEY,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",['Advertising expenses'],"['Advertising expenses', 0.9451526403427124, 'What is $735 million ?', 'Advertising expenses']",Advertising expenses,0.9451526403427124,What is $735 million ?,Advertising expenses,"Advertising expenses

Entity: 
$795 million
Phrase: 
Advertising expenses

Entity: 
$784 million
Phrase: 
Advertising expenses"
12,"We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",795,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,gild,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$795 million and $784 million,MONEY,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",['Advertising expenses'],"['Advertising expenses', 0.9674121737480164, 'What is $795 million and $784 million ?', 'Advertising expenses']",Advertising expenses,0.9674121737480164,What is $795 million and $784 million ?,Advertising expenses,"Advertising expenses for the years ended December 31, 2020 and 2019"
13,"We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",784,['Advertising expense'],us-gaap_AdvertisingExpense,monetaryItemType,gild,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$795 million and $784 million,MONEY,"Advertising expenses were $735 million, $795 million and $784 million for the years ended December 31, 2021, 2020 and 2019, respectively.",['Advertising expenses'],"['Advertising expenses', 0.9674121737480164, 'What is $795 million and $784 million ?', 'Advertising expenses']",Advertising expenses,0.9674121737480164,What is $795 million and $784 million ?,Advertising expenses,"Advertising expenses for the years ended December 31, 2020 and 2019"
14,"Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",851,['Revenues recognized from performance obligations satisfied in prior years'],us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod,monetaryItemType,gild,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$851 million,MONEY,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.","['royalties for licenses', 'licenses of intellectual property', 'intellectual property']","['royalties for licenses of our intellectual property', 0.44413745403289795, 'What is $851 million ?', 'royalties for licenses of our intellectual property']",royalties for licenses of our intellectual property,0.4441374540328979,What is $851 million ?,royalties for licenses of our intellectual property,"Collaborations and Other Arrangements

Entity:
$841 million
Phrase: 
Royalties for licenses of our intellectual property"
15,"Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",841,['Revenues recognized from performance obligations satisfied in prior years'],us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod,monetaryItemType,gild,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$841 million,MONEY,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.","['royalties for licenses', 'licenses of intellectual property', 'intellectual property']","['royalties for licenses of our intellectual property', 0.5125494599342346, 'What is $841 million ?', 'royalties for licenses of our intellectual property']",royalties for licenses of our intellectual property,0.5125494599342346,What is $841 million ?,royalties for licenses of our intellectual property,Collaborations and Other Arrangements
16,"Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",741,['Revenues recognized from performance obligations satisfied in prior years'],us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod,monetaryItemType,gild,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.",$741 million,MONEY,"Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.","['royalties for licenses', 'licenses of intellectual property', 'intellectual property']","['royalties for licenses of our intellectual property', 0.2347477823495865, 'What is $741 million ?', 'royalties for licenses of our intellectual property']",royalties for licenses of our intellectual property,0.2347477823495865,What is $741 million ?,royalties for licenses of our intellectual property,royalties for licenses of our intellectual property
17,"Revenues from product sales, net of gross to net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.",856,['Revenues recognized'],us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice,monetaryItemType,gild,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.",$856 million,MONEY,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.","['Changes in estimates', 'increase in revenues', 'increase for years']","['$101 million', 0.45762714743614197, 'What is $856 million ?', '$101 million']",$101 million,0.4576271474361419,What is $856 million ?,$101 million,"Sales made in prior years

Entity:
$101 million
Phrase:
Changes in estimates

Entity:
$257 million
Phrase:
Revenues for the years ended December 31"
18,"Revenues from product sales, net of gross to net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.",101,['Revenues recognized'],us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice,monetaryItemType,gild,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.",$101 million and,MONEY,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.","['Changes in estimates', 'increase in revenues', 'increase for years']","['', 0, '', '']",,0.0,,,Changes in estimates related to sales made in prior years
19,"Revenues from product sales, net of gross to net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.",257,['Revenues recognized'],us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice,monetaryItemType,gild,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.",$257 million,MONEY,"Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively.","['Changes in estimates', 'increase in revenues', 'increase for years']","['increase in revenues', 0.9874006509780884, 'what is increase in revenues ?', '$257 million']",increase in revenues,0.9874006509780884,what is increase in revenues ?,$257 million,Changes in estimates related to sales made in prior years
20,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December 31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.",174,['Contract assets'],us-gaap_ContractWithCustomerAssetNet,monetaryItemType,gild,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively.",$174 million and $198 million,MONEY,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively.","['unbilled amounts from arrangements', 'licensing of intellectual property', 'contract assets', 'unbilled amounts', 'intellectual property']","['contract assets', 0.8247697353363037, 'What is $174 million and $198 million ?', 'contract assets']",contract assets,0.8247697353363037,What is $174 million and $198 million ?,contract assets,Contract assets from arrangements where the licensing of intellectual property is the only or predominant performance obligation
21,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December 31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.",198,['Contract assets'],us-gaap_ContractWithCustomerAssetNet,monetaryItemType,gild,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively.",$174 million and $198 million,MONEY,"Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively.","['unbilled amounts from arrangements', 'licensing of intellectual property', 'contract assets', 'unbilled amounts', 'intellectual property']","['contract assets', 0.8247697353363037, 'What is $174 million and $198 million ?', 'contract assets']",contract assets,0.8247697353363037,What is $174 million and $198 million ?,contract assets,Contract assets consisting of unbilled amounts
22,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",610,['Unrealized loss on investment of equity securities'],us-gaap_EquitySecuritiesFvNiUnrealizedLoss,monetaryItemType,gild,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",$610 million and,MONEY,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income , net, on our Consolidated Statements of Income.","['Changes in fair value', 'fair value of equity securities', 'net unrealized losses', 'net unrealized gains', 'net unrealized gains for years', 'Consolidated Statements of Income', 'fair value', 'equity securities', 'net unrealized losses', 'Other income', 'Consolidated Statements']","['fair value of equity securities', 0.5530381202697754, 'what is fair value of equity securities ?', 'net unrealized losses of $610 million and $1.7 billion']",fair value of equity securities,0.5530381202697754,what is fair value of equity securities ?,net unrealized losses of $610 million and $1.7 billion,"net unrealized losses
Entity:
$1.7 billion
Phrase:
net unrealized losses
Entity:
$1.2 billion
Phrase:
net unrealized gains"
23,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",1.7,['Unrealized loss on investment of equity securities'],us-gaap_EquitySecuritiesFvNiUnrealizedLoss,monetaryItemType,gild,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",$1.7 billion,MONEY,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income , net, on our Consolidated Statements of Income.","['Changes in fair value', 'fair value of equity securities', 'net unrealized losses', 'net unrealized gains', 'net unrealized gains for years', 'Consolidated Statements of Income', 'fair value', 'equity securities', 'net unrealized losses', 'Other income', 'Consolidated Statements']","['fair value of equity securities', 0.5530381202697754, 'what is fair value of equity securities ?', 'net unrealized losses of $610 million and $1.7 billion']",fair value of equity securities,0.5530381202697754,what is fair value of equity securities ?,net unrealized losses of $610 million and $1.7 billion,Net unrealized losses
24,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",1.2,['Unrealized gain on investment of equity securities'],us-gaap_EquitySecuritiesFvNiUnrealizedGain,monetaryItemType,gild,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.",$1.2 billion,MONEY,"Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December 31, 2021, 2020 and 2019 respectively, which were included in Other income , net, on our Consolidated Statements of Income.","['Changes in fair value', 'fair value of equity securities', 'net unrealized losses', 'net unrealized gains', 'net unrealized gains for years', 'Consolidated Statements of Income', 'fair value', 'equity securities', 'net unrealized losses', 'Other income', 'Consolidated Statements']","['net unrealized gains for years', 0.9873527884483337, 'what is net unrealized gains for years ?', '$1.2 billion']",net unrealized gains for years,0.9873527884483336,what is net unrealized gains for years ?,$1.2 billion,Net unrealized gains
25,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables. These amounts were included in Other long term assets on our Consolidated Balance Sheets.",338,['Other equity investments without readily determinable fair values'],us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount,monetaryItemType,gild,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables.",$338 million,MONEY,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables.","['method investments without determinable fair values', 'method investments', 'determinable fair values', 'above tables']","['determinable fair values', 0.45696762204170227, 'what is determinable fair values ?', '$338 million and $262 million']",determinable fair values,0.4569676220417022,what is determinable fair values ?,$338 million and $262 million,"Equity method investments

Entity: 
$262 million 
Phrase: 
Other equity investments"
26,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables. These amounts were included in Other long term assets on our Consolidated Balance Sheets.",262,['Other equity investments without readily determinable fair values'],us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount,monetaryItemType,gild,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables.",$262 million,MONEY,"Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December 31, 2021 and 2020, respectively, and were excluded from the above tables.","['method investments without determinable fair values', 'method investments', 'determinable fair values', 'above tables']","['determinable fair values', 0.45696762204170227, 'what is determinable fair values ?', '$338 million and $262 million']",determinable fair values,0.4569676220417022,what is determinable fair values ?,$338 million and $262 million,Equity method investments
27,"During the second quarter of 2021, we donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the ""Foundation""). The Foundation is a related party as certain officers of the company also serve as directors of the Foundation. The donation expense of $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.",212,['Donation expense'],us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty,monetaryItemType,gild,"The donation expense of $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.",$212 million,MONEY,"The donation expense of $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.","['donation expense', 'general expenses on Consolidated Statements', 'Consolidated Statements of Income', 'donation expense']","['donation expense', 0.8078490495681763, 'what is donation expense ?', '$212 million']",donation expense,0.8078490495681763,what is donation expense ?,$212 million,Donation expense
28,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",28.6,['Short term and long term debt'],us-gaap_LongTermDebtFairValue,monetaryItemType,gild,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",approximately $28.6 billion,MONEY,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.","['total estimated fair values of aggregate short term', 'total fair values', 'aggregate short term', 'market values']","['fair values of our aggregate short term and long term debt', 0.1722937822341919, 'What is approximately $28.6 billion ?', 'fair values of our aggregate short term and long term debt']",fair values of our aggregate short term and long term debt,0.1722937822341919,What is approximately $28.6 billion ?,fair values of our aggregate short term and long term debt,"Short term debt

Entity: 
approximately $34.6 billion
Phrase: 
Long term debt"
29,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",34.6,['Short term and long term debt'],us-gaap_LongTermDebtFairValue,monetaryItemType,gild,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",$34.6 billion,MONEY,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.","['total estimated fair values of aggregate short term', 'total fair values', 'aggregate short term', 'market values']","['total estimated fair values of aggregate short term', 0.3385101556777954, 'what is total estimated fair values of aggregate short term ?', '$28.6 billion and $34.6 billion']",total estimated fair values of aggregate short term,0.3385101556777954,what is total estimated fair values of aggregate short term ?,$28.6 billion and $34.6 billion,Long term debt estimated fair value
30,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",25.6,['Short term and long term debt'],us-gaap_DebtInstrumentCarryingAmount,monetaryItemType,gild,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",$25.6 billion,MONEY,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.","['total estimated fair values of aggregate short term', 'total fair values', 'aggregate short term', 'market values']","['', 0, '', '']",,0.0,,,"Short term debt carrying value as of December 31, 2021"
31,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",30.3,['Short term and long term debt'],us-gaap_DebtInstrumentCarryingAmount,monetaryItemType,gild,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.",$30.3 billion,MONEY,"The total estimated fair values of our aggregate short term and long term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December 31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December 31, 2021 and 2020, respectively.","['total estimated fair values of aggregate short term', 'total fair values', 'aggregate short term', 'market values']","['', 0, '', '']",,0.0,,,Long term debt carrying value
32,"In connection with our first quarter 2021 acquisition of MYR, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, except for the liability for contingent consideration. The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability weighted scenarios for U.S. Food and Drug Administration (""FDA"") approval of Hepcludex. See Note 6. Acquisitions for additional information.",341,['Liability for MYR GmbH  contingent consideration'],us-gaap_BusinessCombinationContingentConsiderationLiability,monetaryItemType,gild,"The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively.",$341 million,MONEY,"The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively.","['estimated fair value of liability', 'liability for contingent consideration', 'fair value', 'contingent consideration', 'acquisition date']","['estimated fair value of liability', 0.7550246715545654, 'what is estimated fair value of liability ?', '$341 million']",estimated fair value of liability,0.7550246715545654,what is estimated fair value of liability ?,$341 million,The estimated fair value of the liability for contingent consideration.
33,"In connection with our first quarter 2021 acquisition of MYR, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, except for the liability for contingent consideration. The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability weighted scenarios for U.S. Food and Drug Administration (""FDA"") approval of Hepcludex. See Note 6. Acquisitions for additional information.",317,['Liability for MYR GmbH  contingent consideration'],us-gaap_BusinessCombinationContingentConsiderationLiability,monetaryItemType,gild,"The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively.",$317 million,MONEY,"The estimated fair value of the liability for contingent consideration was $341 million and $317 million as of the acquisition date and December 31, 2021, respectively.","['estimated fair value of liability', 'liability for contingent consideration', 'fair value', 'contingent consideration', 'acquisition date']","['fair value of the liability for contingent consideration', 0.07707926630973816, 'What is $317 million ?', 'fair value of the liability for contingent consideration']",fair value of the liability for contingent consideration,0.0770792663097381,What is $317 million ?,fair value of the liability for contingent consideration,Contingent consideration liability
34,"In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (""Immunomedics""), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.",1.3,['Future royalties'],us-gaap_AccruedRoyaltiesCurrentAndNoncurrent,monetaryItemType,gild,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.",$1.3 billion,MONEY,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.","['fair values of liability', 'sale of future royalties', 'fair values', 'future royalties', 'carrying value']","['sale of future royalties', 0.7444220781326294, 'what is sale of future royalties ?', '$1.3 billion']",sale of future royalties,0.7444220781326294,what is sale of future royalties ?,$1.3 billion,Liability related to the sale of future royalties
35,"In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (""Immunomedics""), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.",1.1,['Future royalties'],us-gaap_AccruedRoyaltiesCurrentAndNoncurrent,monetaryItemType,gild,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.",$1.1 billion,MONEY,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.","['fair values of liability', 'sale of future royalties', 'fair values', 'future royalties', 'carrying value']","['carrying value', 0.9525424242019653, 'what is carrying value ?', '$1.1 billion']",carrying value,0.9525424242019652,what is carrying value ?,$1.1 billion,"Carrying value as of December 31, 2020"
36,"In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (""Immunomedics""), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.",1.1,['Future royalties'],us-gaap_AccruedRoyaltiesCurrentAndNoncurrent,monetaryItemType,gild,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.",$1.1 billion,MONEY,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.","['fair values of liability', 'sale of future royalties', 'fair values', 'future royalties', 'carrying value']","['carrying value', 0.9525424242019653, 'what is carrying value ?', '$1.1 billion']",carrying value,0.9525424242019652,what is carrying value ?,$1.1 billion,"The carrying value as of December 31, 2020"
37,"In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (""Immunomedics""), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.",1.1,['Future royalties'],us-gaap_AccruedRoyaltiesCurrentAndNoncurrent,monetaryItemType,gild,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.",$1.1 billion,MONEY,"The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December 31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December 31, 2021 and 2020.","['fair values of liability', 'sale of future royalties', 'fair values', 'future royalties', 'carrying value']","['carrying value', 0.9525424242019653, 'what is carrying value ?', '$1.1 billion']",carrying value,0.9525424242019652,what is carrying value ?,$1.1 billion,Liability related to the sale of future royalties
38,"In 2019, we measured IPR&D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (""Kite"") at fair value on a nonrecurring basis, and recognized a pre tax impairment charge of $800 million. The fair values of the acquired IPR&D assets are estimated based on probability adjusted discounted cash flow calculations using Level 3 fair value measurements, and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&D are subject to impairment testing until the completion or abandonment of the associated R&D efforts. See Note 9. Goodwill and Intangible Assets for additional information.",800,['In process research and development impairment'],us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill,monetaryItemType,gild,"In 2019, we measured IPR&D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (“Kite”) at fair value on a nonrecurring basis, and recognized a pre tax impairment charge of $800 million.",$800 million,MONEY,"In 2019, we measured IPR&D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc.  at fair value on a nonrecurring basis, and recognized a pre tax impairment charge of $800 million.","['connection with acquisition', 'acquisition of Kite Pharma', 'impairment charge', 'intangible assets', 'fair value', 'nonrecurring basis', 'impairment charge']","['pre tax impairment charge', 0.7989616990089417, 'What is $800 million ?', 'pre tax impairment charge']",pre tax impairment charge,0.7989616990089417,What is $800 million ?,pre tax impairment charge,Pre tax impairment charge
39,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively. Aggregated gross unrealized losses on available for sale debt securities were not material for the years ended December 31, 2021 and 2020. No impairment was recognized for the years ended December 31, 2021, 2020 and 2019.",534,"['Securities in unrealized loss positions, number of positions']",us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions,integerItemType,gild,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively.",534 and 75,CARDINAL,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively.","['total of positions', 'unrealized loss positions']","['total of positions', 0.5600318312644958, 'how many total of positions ?', '534 and 75']",total of positions,0.5600318312644958,how many total of positions ?,534 and 75,Unrealized loss positions
40,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively. Aggregated gross unrealized losses on available for sale debt securities were not material for the years ended December 31, 2021 and 2020. No impairment was recognized for the years ended December 31, 2021, 2020 and 2019.",75,"['Securities in unrealized loss positions, number of positions']",us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions,integerItemType,gild,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively.",534 and 75,CARDINAL,"We held a total of 534 and 75 positions which were in unrealized loss positions as of December 31, 2021 and 2020, respectively.","['total of positions', 'unrealized loss positions']","['total of positions', 0.5600318312644958, 'how many total of positions ?', '534 and 75']",total of positions,0.5600318312644958,how many total of positions ?,534 and 75,Unrealized loss positions
41,"We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December 31, 2021 are expected to be reclassified to Product sales within 12 months.",18,['Maturity on derivative instruments'],us-gaap_DerivativeRemainingMaturity1,durationItemType,gild,The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less.,18 months,DATE,The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less.,"['maturities of less months', 'derivative instruments', 'flow hedges', 'less months']","['maturities', 0.9811719059944153, 'What is 18 months ?', 'maturities']",maturities,0.9811719059944152,What is 18 months ?,maturities,Derivative instruments cash flow hedges
42,"We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December 31, 2021 are expected to be reclassified to Product sales within 12 months.",12,['Time estimate for gains  to be reclassified from AOCI to product sales'],us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1,durationItemType,gild,"The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December 31, 2021 are expected to be reclassified to Product sales within 12 months.",12 months,DATE,"The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December 31, 2021 are expected to be reclassified to Product sales within 12 months.","['majority of gains', 'Product sales']","['Product sales', 0.9183069467544556, 'What is 12 months ?', 'Product sales']",Product sales,0.9183069467544556,What is 12 months ?,Product sales,Gains and losses related to hedged forecasted transactions
43,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.",2.9,['Outstanding notional amounts on foreign currency exchange contracts'],us-gaap_DerivativeNotionalAmount,monetaryItemType,gild,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.",$2.9 billion and,MONEY,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.","['notional amounts on exchange outstanding contracts', 'notional amounts', 'exchange outstanding contracts']","['foreign currency exchange contracts', 0.8218220472335815, 'What is $2.9 billion and ?', 'foreign currency exchange contracts']",foreign currency exchange contracts,0.8218220472335815,What is $2.9 billion and ?,foreign currency exchange contracts, foreign currency exchange contracts outstanding
44,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.",2.4,['Outstanding notional amounts on foreign currency exchange contracts'],us-gaap_DerivativeNotionalAmount,monetaryItemType,gild,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.",$2.4 billion,MONEY,"We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December 31, 2021 and 2020, respectively.","['notional amounts on exchange outstanding contracts', 'notional amounts', 'exchange outstanding contracts']","['foreign currency exchange contracts', 0.8328355550765991, 'What is $2.4 billion ?', 'foreign currency exchange contracts']",foreign currency exchange contracts,0.8328355550765991,What is $2.4 billion ?,foreign currency exchange contracts,Foreign currency exchange contracts outstanding
45,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317 million as of December 31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.",1.3,['Consideration'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,gild,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.",$€1.3 billion,MONEY,"The aggregate consideration for this acquisition of €1.3 billion or $1.6 billion primarily consisted of €1.0 billion or $1.2 billion paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.","['aggregate consideration for acquisition', 'acquisition', 'consideration', 'FDA approval of Hepcludex', 'aggregate consideration', 'customary adjustments', 'potential milestone payment', 'FDA approval']","['', 0, '', '']",,0.0,,,Aggregate consideration for acquisition
46,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317 million as of December 31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.",1.6,['Consideration'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,gild,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.",$1.6 billion,MONEY,"The aggregate consideration for this acquisition of €1.3 billion or $1.6 billion primarily consisted of €1.0 billion or $1.2 billion paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.","['aggregate consideration for acquisition', 'acquisition', 'consideration', 'FDA approval of Hepcludex', 'aggregate consideration', 'customary adjustments', 'potential milestone payment', 'FDA approval']","['', 0, '', '']",,0.0,,,Aggregate consideration for acquisition
47,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317 million as of December 31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.",1.0,['Cash payments made for acquisition'],us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,gild,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.",$€1.0 billion,MONEY,"The aggregate consideration for this acquisition of €1.3 billion or $1.6 billion primarily consisted of €1.0 billion or $1.2 billion paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.","['aggregate consideration for acquisition', 'acquisition', 'consideration', 'FDA approval of Hepcludex', 'aggregate consideration', 'customary adjustments', 'potential milestone payment', 'FDA approval']","['', 0, '', '']",,0.0,,,paid upon closing
48,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317 million as of December 31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.",1.2,['Cash payments made for acquisition'],us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,gild,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.",$1.2 billion,MONEY,"The aggregate consideration for this acquisition of €1.3 billion or $1.6 billion primarily consisted of €1.0 billion or $1.2 billion paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.","['aggregate consideration for acquisition', 'acquisition', 'consideration', 'FDA approval of Hepcludex', 'aggregate consideration', 'customary adjustments', 'potential milestone payment', 'FDA approval']","['', 0, '', '']",,0.0,,,Paid upon closing
49,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317 million as of December 31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.",300,['Liability for MYR GmbH  contingent consideration'],us-gaap_BusinessCombinationContingentConsiderationLiability,monetaryItemType,gild,"The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.",$up to €300 million,MONEY,"The aggregate consideration for this acquisition of €1.3 billion or $1.6 billion primarily consisted of €1.0 billion or $1.2 billion paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex.","['aggregate consideration for acquisition', 'acquisition', 'consideration', 'FDA approval of Hepcludex', 'aggregate consideration', 'customary adjustments', 'potential milestone payment', 'FDA approval']","['', 0, '', '']",,0.0,,,contingent consideration
